- Home
- JSPR vs TVRD Comparison
JSPR vs TVRD Comparison
Compare JSPR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | TVRD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JSPR | TVRD |
|---|---|---|
| Price | $1.55 | $3.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $18.13 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 975.8K | 100.0K |
| Earning Date | 02-26-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $3.74 |
| 52 Week High | $7.19 | $43.65 |
Technical Indicators
Market Signals| Indicator | JSPR | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 35.92 |
| Support Level | $1.51 | $4.39 |
| Resistance Level | $1.66 | $4.89 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 45.19 | 4.85 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.